The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
chemoradiation
combination chemotherapy
conversion surgery
induction chemotherapy
local response
pancreatic ductal adenocarcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Sep 2021
21 Sep 2021
Historique:
received:
20
08
2021
revised:
14
09
2021
accepted:
20
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
An optimal therapeutic strategy for unresectable locally advanced pancreatic cancer (UR-LAPC) has not been established. This study investigated the therapeutic efficacy of chemoradiotherapy (CRT) following induction chemotherapy with gemcitabine plus nab-paclitaxel (GnP) (CRT group) compared with systemic chemotherapy alone (CTx group) in patients with UR-LAPC. This was a retrospective study of 63 consecutive patients with UR-LAPC treated at our department in a Japanese cancer referral center between February 2015 and July 2018. We excluded patients who underwent other regimens and those enrolled in another prospective study. The CRT group (
Identifiants
pubmed: 34572960
pii: cancers13184733
doi: 10.3390/cancers13184733
pmc: PMC8470784
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Gastroenterol. 2020 Apr;55(4):369-382
pubmed: 31997007
Ther Adv Med Oncol. 2020 Sep 16;12:1758835920953294
pubmed: 32983266
ESMO Open. 2021 Apr;6(2):100049
pubmed: 33578192
J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):590-600
pubmed: 23660962
JGH Open. 2021 May 10;5(6):679-685
pubmed: 34124386
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
ESMO Open. 2020 Nov;5(6):e000929
pubmed: 33229503
J Clin Oncol. 2007 Jan 20;25(3):326-31
pubmed: 17235048
Ann Oncol. 2008 Sep;19(9):1592-9
pubmed: 18467316
Pancreas. 2018 Oct;47(9):1135-1141
pubmed: 30134354
Pancreatology. 2020 Jul;20(5):919-928
pubmed: 32563596
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Expert Rev Anticancer Ther. 2011 Oct;11(10):1555-65
pubmed: 21999129
J Clin Oncol. 2011 Nov 1;29(31):4105-12
pubmed: 21969502
Int J Clin Oncol. 2020 Jun;25(6):1010-1015
pubmed: 32303874
Jpn J Clin Oncol. 2021 Feb 8;51(2):235-243
pubmed: 33164066
World J Gastroenterol. 2014 Mar 7;20(9):2255-66
pubmed: 24605025
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e143-9
pubmed: 23200173
Cancers (Basel). 2020 Jul 18;12(7):
pubmed: 32708493
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138
pubmed: 33338442
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294
pubmed: 31953079
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Pancreatology. 2019 Mar;19(2):296-301
pubmed: 30638853
Ann Surg Oncol. 2017 May;24(5):1406-1413
pubmed: 27896518